Overview
Javascript is curently disabled in your browser. Several features of this site wil not function whilst javascript is disabled.open aces to scientific and medical researchPapers PublishedOpen aces per-reviewed scientific and medical journals.Learn moreDove Medical Pres is a member of the OAI.Learn moreBulk reprints for the pharmaceutical industry.Learn moreWe ofer real benefits to our authors, including fast-track procesing of papers.Learn moreRegister your specific details and specific drugs of interest and we wil match the information you provide to articles from our extensive database and email PDF copies to you promptly.Learn moreBack to Journals » OncoTargets and Therapy » Volume 15 Authors Leung M , Rodrigues P, Roitman D Received 1 April 202 Acepted for publication 9 August 202 Published 28 October 202 Volume 202:15 Pages 1309—1315 DOI htps:/doi.org/10.2147/OT.S37024 Checked for plagiarism Yes Review by Single anonymous per review Per reviewer coments 2 Editor who aproved publication: Dr Sanjev Srivastava Mova Leung,1,2 Paulina Rodrigues,2 Daryl Roitman1 1Cancer Care Program, North York General Hospital, Toronto, Ontario, Canada; 2Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, CanadaCorespondence: Mova Leung, Email [email protected]Background: Diabetic ketoacidosis (DKA) is a rare complication of alpelisib, but cases of DKA are reported.
Key Information
Alpelisib’s safety in patients with long-standing, suboptimaly controled diabetes is unclear since clinical trials of alpelisib did not include them.Case: A case is presented on a patient with metastatic breast cancer and type 2 diabetes admited for DKA eleven days after starting alpelisib. Since DKA is implicated in antihyperglycemics that inhibit sodium-glucose cotransporter-2 (SGLT2) inhibitors, her empagliflozin was discontinued.
Summary
Alpelisib was also held since it was recently initiated. After the DKA resolved, she was discharged and restarte